Defendant Name:
Becton, Dickinson and Company
Defendant Type:
Public Company
SIC Code:
3841
CUSIP:
07588710
Document Reference:
33-11344
Document Details
Legal Case Name
In the Matter of Becton, Dickinson and Company
Document Name
Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8A of the Securities Act of 1933 and Section 21C of the Securities Exchange Act of 1934, Making Findings, and Imposing a Cease-and-Desist Order
Document Date
16-Dec-2024
Document Format
Administrative Proceeding
AAER
4547
Allegation Type
Issuer Reporting and Disclosure
Document Summary
On December 16, 2025, the SEC instituted settled cease-and-desist proceedings against Becton, Dickinson and Company, stating: "This matter involves Becton Dickinson’s repeated misrepresentations to investors regarding the risks it was taking in selling one of its most important products. From 2016 to early 2020, BD understood its Alaris infusion pump, whose sales contributed about 10% of BD’s profits, required new regulatory clearance from the FDA to address historical changes to the device and to fix multiple software flaws that posed safety risks to patients. BD misrepresented these risks and failed to disclose the risk that the FDA would prohibit sales of Alaris until the company obtained new clearance and fixed its software. BD also overstated its income by failing to properly account for the costs of fixing the device."
Disgorgement & Penalty Information
Resolutions
Cease and Desist Order
Compliance Related Independent Consultant
Fair Funds
Monetary Penalties:
Civil Penalty
Individual:
$175,000,000.00
Shared:
